Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November

October 11, 2022

- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy -
- Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of ADG116 across dosing levels, with repeat dosing both as monotherapy and in combination with anti-PD-1 therapy -
- Posters include new details of responses in monotherapy and combination therapy in tumor types where current anti-CTLA-4 therapy is not approved -

SAN DIEGO and SUZHOU, China, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that it will present clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, at the upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place November 8-12 in Boston.

The posters will summarize the comprehensive safety data for ADG116 with repeat dosing as monotherapy, as well as new data supporting its optimal dose selection in combination with two different anti-PD-1 therapies. Additionally, data will show anti-tumor activity in warm and cold tumors, including details of a partial response with monotherapy and a complete response in combination therapy, which were both observed in tumor types where no anti-CTLA-4 therapy is approved.

Details for the poster presentations include:

- **Title:** A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObody™ADG116 Monotherapy and in Combination with Toripalimab (Tori; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
  - Date: Thursday, November 10, 2022 (abstract publication on November 7)
  - Poster Session: 9:00 a.m. – 9:00 p.m. Eastern Time (ET)
  - Onsite Location: Poster Hall
  - Abstract Poster Number: 753

- **Title:** A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEObody™ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update
  - Date: Thursday, November 10, 2022 (abstract publication on November 7)
  - Poster Session: 9:00 a.m. – 9:00 p.m. ET
  - Onsite Location: Poster Hall
  - Abstract Poster Number: 773

Both posters will be published on the company’s website at [www.adagene.com/pipeline/publications](http://www.adagene.com/pipeline/publications) in accordance with the SITC embargo policy on November 10, 2022.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: [https://investor.adagene.com](https://investor.adagene.com). Follow Adagene on WeChat, LinkedIn and Twitter.

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding certain clinical results of ADG116, the potential implications of clinical results of the product candidate, and Adagene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of Adagene pipeline candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in
Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Investor & Media Contact:
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com

Source: Adagene Inc.